Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 292Urinary Bladder Neoplasms 39Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 24Carcinoma, Transitional Cell 23Neoplasms 21Breast Neoplasms 20Lung Neoplasms 13Carcinoma, Renal Cell 13Ovarian Neoplasms 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Non-Muscle Invasive Bladder Neoplasms 10Melanoma 9Small Cell Lung Carcinoma 7Salivary Gland Neoplasms 7Prostatic Neoplasms, Castration-Resistant 7Head and Neck Neoplasms 7Esthesioneuroblastoma, Olfactory 7Esophageal Neoplasms 7Colorectal Neoplasms 7Urethral Neoplasms 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Prostate Cancer Metastatic 5Pancreatic Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Kidney Neoplasms 5Adenocarcinoma 5Sarcoma 4

Interventions

padeliporfin 4darolutamide 2apalutamide 2Abiraterone Acetate 2palladium-bacteriopheophorbide 1onapristone 1niraparib 1ixabepilone 1gedatolisib 1gallium 68 PSMA-11 1enzalutamide 1abiraterone 1Therapeutics 1Standard of Care 1Radiotherapy 1Prednisone 1Pluvicto 1Imatinib Mesylate 1EPI-506 1Docetaxel 1BAY 86-7548 1Androgen Antagonists 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Diseases, Male × Docetaxel × Genitourinary × Clear all
NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡